RSV vaccine safety study in adults 18 and older
Part of Infections clinical trials.
This trial tests a new vaccine against respiratory syncytial virus (RSV), a common virus that can cause lung infections. It is for healthy adults aged 18 and older, to see if the vaccine is safe and produces a good immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and live in the local area.
- You need to be able to read and understand the consent form, and follow study instructions, like filling out a diary card.
- If you are a woman who can have children, you must have used reliable contraception for 2 weeks before the study, have a negative pregnancy test, and agree to use contraception for 6 months after the shot. Men must also use contraception with female partners for 6 months after vaccination.
- You should be generally healthy, with no serious or unstable medical conditions (like uncontrolled high blood pressure, heart rhythm problems, or a weakened immune system).
- You must not have had an RSV infection in the last year, or ever received an RSV vaccine or RSV antibody treatment.
- You should not be pregnant, breastfeeding, or planning pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This study tests a new vaccine designed to protect against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. The vaccine is given as a shot, and the study will check how your immune system responds to it.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This trial tests an experimental vaccine against respiratory syncytial virus (RSV) in children who are at high risk of serious RSV illness due to chronic medical conditions or weakened immune systems. The goal is to see if the vaccine is safe and effective in preventing RSV-related lower respiratory tract infections.
This study tests a new vaccine that may protect babies from a common breathing virus called RSV. It is given to healthy women to see if it is safe and if it helps the body make protection that could be passed to a baby during pregnancy.
This study tests a new RSV vaccine called YKYY025 in healthy adults. The main goal is to see if it is safe and to measure how the immune system responds.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.